Comparative Pharmacology
Head-to-head clinical analysis: M V I 12 ADULT versus RUVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: M V I 12 ADULT versus RUVITE.
M.V.I.-12 ADULT vs RUVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
M.V.I.-12 Adult is a multivitamin combination that supplies essential vitamins (A, D, E, C, B1, B2, B3, B5, B6, B12, folic acid, biotin) to maintain normal metabolic functions, act as cofactors in enzymatic reactions, and support cellular respiration, antioxidant defense, and erythropoiesis.
RUVITE (ruxolitinib) is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2, which mediates signaling of cytokines and growth factors involved in hematopoiesis and immune function.
10 mL (one vial) added to 500 mL of IV fluid, infused over 8-24 hours once daily.
100 mg orally once daily with or without food.
None Documented
None Documented
Variable by component: e.g., thiamine 9-18 days (tissue stores), vitamin C 10-20 days (depletion), vitamin A 50-100 days (liver stores). Clinical context: half-lives reflect slow depletion; daily dosing maintains plasma levels.
The terminal elimination half-life is approximately 2-4 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged to 8-12 hours, necessitating dose adjustment.
Renal: water-soluble vitamins (B-complex, C) excreted in urine; fat-soluble vitamins (A, D, E, K) undergo biliary/fecal excretion. Specific percentages vary per component; e.g., vitamin C ~50% renal, thiamine ~30-70% renal as metabolites.
Renal excretion of unchanged drug accounts for approximately 30-50% of the administered dose; biliary/fecal elimination accounts for the remainder, with 20-30% recovered in feces as metabolites and parent drug. Total clearance is about 100-150 mL/min.
Category C
Category C
Multivitamin
Multivitamin